Management of necrotizing vasculitis with colchicine. Improvement in patients with cutaneous lesions and Behcet's syndrome

Abstract

Six patients with necrotizing vasculitis were treated with oral colchicine as part of an open study. Four patients with cutaneous vasculitis and normal levels of serum complement and one patient with vasculitis associated with Behcet's syndrome demonstrated clinical improvement while receiving colchicine. One patient with cryoglobulinemia, hypocomplementemia, and cutaneous vasculitis showed no response to colchicine therapy. In three patients, clinical improvement persisted after its withdrawal. Colchicine may be effective in controlling cutaneous necrotizing vasculitis and Behcet's syndrome through its effect on polymorphnuclear leukocyte function.

Colchicine Revisited

“…Five out of six patients treated for this condition with oral colchicine showed clinical improvement. In three of the patients, the clinical improvement persisted even after stopping the drug 26 …”

Colchicine-induced rhabdomyolysis: a review of 83 cases

“…It is derived from the plant Colchicum autumnale . The medication is used for the treatment of gout, FMF, pericarditis and Behcet disease 1–3 8. Tubulin disruption leading to downregulation of multiple inflammatory pathways and modulation of innate immunity is the primary mechanism of action 9.…”

Colchicine versus placebo in Behçet’s disease: randomized, double-blind, controlled crossover trial

“…The daily experiences and the general feelings of experts are that colchicine is of some use in BD, mainly for mucocutaneous lesions [1][2][3][4][5][6][7][8][12][13][14]. While it is rare to observe complete remission with colchicine, lesions usually become less awkward, exhibiting shorter healing times and longer remission periods.…”